✦ LIBER ✦

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

✍ Scribed by José Baselga, Frederico Costa, Henry Gomez, Clifford A Hudis, Bernardo Rapoport…

Book ID: 120704197
Publisher: BioMed Central
Year: 2013
Tongue: English
Weight: 246 KB
Volume: 14
Category: Article
ISSN: 1468-6708
DOI: 10.1186/1745-6215-14-228

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

257 Design of RESILIENCE: a Phase 3 TRia

257 Design of RESILIENCE: a Phase 3 TRial Comparing CapecitabinE in Combination with SorafenIb or PLacebo for Treatment of Locally Advanced or MetastatIc HER2-Negative Breast CancEr

✍ J. Baselga; F. Costa; H. Gomez; C. Hudis; B. Rapoport; H. Roche; L.S. Schwartzbe 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Sorafenib in Combination With Capecitabi

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

✍ Baselga, J.; Segalla, J. G. M.; Roche, H.; del Giglio, A.; Pinczowski, H.; Cirue 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 177 KB

Safety results from a phase III study (T

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

✍ I. Lang; M.J. Inbar; Z. Kahán; R. Greil; S. Beslija; S.M. Stemmer; B. Kaufman; Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Phase II Interventional Study (N0337) of

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

✍ Winston W. Tan; Jacob B. Allred; Muhammad Salim; Patrick Flynn; Paul A.S. Fishki 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 354 KB

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Brufsky, A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 99 KB